Teleflex Inc is a leading global provider of medical technologies designed to enhance the health and well-being of patients. With a diverse product portfolio, the company specializes in the development, manufacturing, and distribution of innovative medical devices for a wide range of applications. Teleflex focuses on delivering high-quality solutions in critical care, surgical care, urology, and respiratory care, among others. By leveraging its expertise and strong market presence, Teleflex continuously aims to improve patient outcomes, increase healthcare efficiency, and advance medical innovation.

Teleflex Inc is primarily active in a variety of industries. As a global provider of medical technology products, the company focuses on healthcare, providing innovative solutions in the areas of surgical and diagnostic devices, anesthesia, and critical care. Teleflex Inc also has a presence in the aerospace industry, supplying specialized control systems and components for aircraft and helicopters. With its diverse portfolio, Teleflex Inc continues to make significant contributions in these sectors, driving advancements and improving patient outcomes in healthcare, while delivering reliable and efficient solutions in the aerospace industry.

The main competitors of Teleflex Inc in the market include Johnson & Johnson, Becton, Dickinson and Company, Medtronic plc, and Smiths Medical.

Teleflex Inc is a renowned company specializing in medical technology. Established in 1943, Teleflex has a rich history rooted in innovation and industry leadership. With headquarters in Wayne, Pennsylvania, the company has expanded globally, offering a diverse portfolio of medical devices that enhance patient care and improve clinical outcomes. Teleflex's dedication to research and development has led to breakthrough solutions in respiratory care, surgical instruments, urology, vascular access, and more. By combining cutting-edge technology with a commitment to quality, Teleflex continues to shape the healthcare industry, providing healthcare professionals with the tools they need to deliver superior patient care.

Teleflex Inc has achieved several significant milestones throughout its history. The company expanded its product portfolio by acquiring Arrow International in 2007, a leading manufacturer of critical care products. In 2011, Teleflex successfully launched the MANTA Vascular Closure Device, revolutionizing the way vascular access sites are closed after procedures. Additionally, the company received FDA clearance for the Teleflex UroLift System in 2013, providing a minimally invasive solution for enlarged prostate patients. In recent years, Teleflex also made significant advancements in its vascular access product line, including the introduction of the ARROW PICC with Chlorag+ard Technology. These achievements highlight Teleflex's continuous commitment to innovation and improving patient outcomes.

Teleflex Inc is primarily present in various countries and regions worldwide. The company has a strong global presence, with operations in North America, Europe, Asia Pacific, and Latin America. Teleflex serves customers and healthcare markets in over 150 countries, providing innovative solutions in medical technology and consumer healthcare. With its diverse portfolio of products and services, Teleflex Inc has established itself as a trusted provider in the medical device industry.

Teleflex Inc represents a set of core values and a corporate philosophy that guide its operations. With a focus on innovation and excellence, the company strives to deliver high-quality medical technology solutions to enhance patient outcomes. Teleflex is committed to providing world-class customer service, ensuring the best user experience for healthcare professionals and patients. With a dedication to integrity, teamwork, and continuous improvement, Teleflex values collaboration, transparency, and ethical conduct in all aspects of its business. By prioritizing customer needs and embracing a culture of innovation, Teleflex aims to make a positive impact in the healthcare industry.

Analysts currently set an average price target of 137,93 USD for the Teleflex stock (median: 131,58 USD), implying +5,2 % versus the latest price. The consensus is based on 18 analyst ratings.

Teleflex Analītiķu cenu mērķi 2026

18 analysts currently rate the Teleflex stock: 5 recommend buying, 12 holding and 1 selling. For 2026, analysts expect Teleflex to generate revenue of 2,29 B USD and earnings per share of 7,12 USD.

Teleflex Analītiķu cenu mērķi 2026

Converted at the current exchange rate, the Teleflex share trades at 115,26 EUR (131,16 USD).

The Teleflex share (TFX) is listed on 6 stock exchanges, including: NYSE (TFX), XETRA (TBH.DE), Frankfurt (TBH.F), München (TBH.MU), Düsseldorf (TBH.DU), SIX (Zürich) (TBH.SW).

Teleflex Inc. is an American company specializing in the manufacturing and selling of medical devices and instruments. It was founded in 1943 and has become a leading provider of medical products. The company divides its business into three main segments: Medical Devices, Anesthesia, and Interventional Medicine. Each segment offers a wide range of products tailored to the specific needs of the healthcare industry. The Medical Devices segment focuses on catheters, leads, drains, and other surgical instruments, while also offering specialized products for cardiology, oncology, and neurology. The Anesthesia segment specializes in products used in anesthesia applications, such as ventilation support devices and block needles. The Interventional Medicine segment focuses on treating and preventing vascular diseases with products like vascular access devices and balloon catheters used in minimally invasive procedures. This segment is the fastest-growing for Teleflex due to increasing demand for minimally invasive treatment methods. Teleflex has built a portfolio of over 30,000 products through acquisitions and internal innovations. Effective management, partnerships with doctors and hospitals, and participation in industry events ensure the company's growth and expansion. In summary, Teleflex Inc. is a company with a wide range of medical products used in various sectors of the healthcare industry. With a global presence and diverse product portfolio, the company can respond to changing customer desires and needs. Through continuous innovation, research, and development, Teleflex aims to revolutionize the healthcare industry and achieve higher levels of effectiveness and efficiency.

gaidāmā apgrozījums Teleflex ir 2,29 B USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.

gaidāmā peļņa Teleflex ir 314,79 M USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.

Teleflex cenas un peļņas rādītājs (P/E) pašlaik ir 18,43. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Teleflex akcijas vērtību.

Teleflex cenas un apgrozījuma rādītājs (P/S) pašlaik ir 2,54. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Teleflex akcijas vērtības mērs.

Teleflex Eulerpool kvalitātes rādītājs ir 1/10.

Teleflex ISIN ir US8793691069. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.

Teleflex WKN ir 855853. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.

Teleflex tikeris ir TFX. Tikeris tiek izmantots Teleflex akciju tirdzniecībai biržā.

Pēdējo 12 mēnešu laikā Teleflex maksāja dividendes 1,36 USD apmērā. Tas atbilst aptuveni 1,04 % dividendes ražībai. Nākamajos 12 mēnešos Teleflex plāno maksāt dividendes 1,36 USD apmērā.

Teleflex pašreizējā dividendu rentabilitāte ir 1,04 %.

Teleflex maksā dividendes, kas tiek sadalītas mēnešos , , , .

Teleflex pēdējo 36 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 1,36 USD. Tas atbilst dividendes ražībai 1,04 %.

Teleflex tiek piešķirts nozarei "Veselība".

Gadā 2025, Teleflex izmaksāja 1,36 USD dividendes.

Teleflex dividendes tiek izmaksātas USD.